18 Oct 2017 - 1:54pm

Call us: +44 (0) 207 754 0050

Press Releases

CHARITYSTARS LAUNCHES 2017 FASHION CAMPAIGN WITH EXCLUSIVE MILAN FASHION WEEK SHOW ACCESS AND MORE

[PRESSWIRE] London, United Kingdom - 5 September, 2017 -- CharityStars.com , the world’s leading online charity auctions website, is offering a number of money can’t buy experiences in the exclusive world of Italian fashion; online now. These include fashion show invites, as well as clothing and accessories auctions.

“Dale Enochs: On the Rocks” Kicks off Long-Sharp Gallery’s Fall 2017 Season

[PRESSWIRE] INDIANAPOLIS, IN - 30 August, 2017 --  Opening September 8, 2017 at Long-Sharp Gallery Indianapolis, “Dale Enochs: On The Rocks” celebrates Bloomington, IN based limestone sculptor Dale Enochs’ decades of sculpting as well as his recent important public sculptures and museum acquisitions. The exhibit runs through September 30.

Two New York Galleries Exhibit New Paintings by Sabina Klein

[PRESSWIRE] New York, NY - 29 August, 2017 --Two galleries in New York’s Gallery Building will host the first solo exhibit in nearly a decade for New Yorker Sabina Klein. Long-Sharp Gallery (suite 606) and John Szoke Gallery (suite 303) present Sabina Klein: On Reflection. The exhibit will open Wednesday, September 6 from 6-8:30 pm and run through October 21, 2017. The Gallery Building is in Midtown at 24 West 57thStreet between 5th and 6th Avenues.

FENICS Market Data Partners with China Credit BGC Money Broking Company Ltd. to Offer Clients China Market Data

[PRESSWIRE] NEW YORK, Aug. 28, 2017 -- FENICS Market Data, the Market Data division of BGC Partners (NASDAQ:BGCP) ("BGC Partners", "BGC", or "the Company"), and China Credit BGC Money Broking Company Limited ("CCT-BGC") have agreed to a distribution partnership, whereby FENICS Market Data will exclusively provide CCT-BGC's Chinese market data products to global clients. 

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US

[PRESSWIRE] TAIPEI, Taiwan and CINCINNATI, Aug. 28, 2017 -- Lumosa Therapeutics Co., Ltd. ("Lumosa"), a Taipei-based biopharmaceutical company developing innovative therapies focused on the treatment of neurological and inflammatory disease, announced today the FDA has confirmed the 505(b)(2) regulatory pathway is appropriate for the submission of the NDA of LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US. 

Pages

Subscribe to Press Releases